Dr. Stevens is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
125 Paterson St
Clinical Academic Building Suite 5200a
New Brunswick, NJ 08901Phone+1 732-235-7217Fax+1 732-212-0713
Education & Training
Roger Williams Medical CenterFellowship, Rheumatology, 1985 - 1987
Brown UniversityResidency, Internal Medicine, 1982 - 1985
Case Western Reserve University School of MedicineClass of 1982
Certifications & Licensure
NJ State Medical License 1987 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Rheumatology
Awards, Honors, & Recognition
- Fellow (FACR) American College of Rheumatology
Clinical Trials
- Study of Apremilast to Evaluate the Safety and Effectiveness for Patients With Rheumatoid Arthritis Start of enrollment: 2010 Dec 09
Publications & Presentations
PubMed
- 1877 citationsEfficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.Jonathan C. W. Edwards, Leszek Szczepanski, Jacek Szechiński, Anna Filipowicz-Sosnowska, Paul Emery
The New England Journal of Medicine. 2004-06-17 - 9 citationsIntravenous human recombinant tumor necrosis factor receptor p55-Fc IgG1 fusion protein, Ro 45-2081 (Lenercept): Results of a dose-finding study in rheumatoid arthritisDaniel E. Furst, Michael H. Weisman, Harold E. Paulus, Kenneth Bulpitt, Michael E. Weinblatt
The Journal of Rheumatology. 2003-10-01 - 15 citationsIntravenous human recombinant tumor necrosis factor receptor p55-Fc IgG1 fusion protein Ro 45-2081 (lenercept): a double blind, placebo controlled dose-finding study i...Rolf Rau, Oliver Sander, Piet L. C. M. van Riel, Leo B A van de Putte, Fritz Hasler
The Journal of Rheumatology. 2003-04-01
Press Mentions
CNTX-4975 Injection Improves OA-Associated Knee PainApril 12th, 2019
Centrexion Therapeutics Announces Fast Track Designation Granted by FDA to CNTX-4975 for Treatment of Morton’s NeuromaFebruary 9th, 2017
Centrexion Therapeutics to Present New Positive Clinical Trial Results on Streamlined CNTX-4975 Administration TechniquesJuly 29th, 2019
Professional Memberships
- Member
- Fellow
Other Languages
- Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
